Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Viral Hepatitis
4.2.2 Favorable Government Support for Creating Awareness about Hepatitis
4.2.3 Increasing Availability of Technologically Advanced Therapeutic Products
4.3 Market Restraints
4.3.1 Stringent Regulatory Issues
4.3.2 Poor Reimbursement Policies
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Disease Type
5.1.1 Hepatitis A
5.1.2 Hepatitis B
5.1.3 Hepatitis C
5.1.4 Hepatitis D
5.1.5 Other Types
5.2 By Drug Class
5.2.1 Interferon
5.2.2 Monoclonal Antibody
5.2.3 Non-structural protein 5A (NS5A) inhibitors
5.2.4 Nucleotide Analog Reverse Transcriptase Inhibitors
5.2.5 Nucleotide Analog NS5B Polymerase Inhibitors
5.2.6 Multi Class Combination
5.2.7 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East-and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co., Inc
6.1.2 Gilead Sciences, Inc
6.1.3 AbbVie Inc
6.1.4 Bristol Myers Squibb Company
6.1.5 F. Hoffmann-La Roche, Ltd
6.1.6 LAURUS Labs
6.1.7 Zydus Cadila
6.1.8 Hetero Healthcare Limited
6.1.9 NATCO Pharma Limited
6.1.10 Cipla, Inc


7 MARKET OPPORTUNITIES AND FUTURE TRENDS